StressMarq Biosciences has developed an extensive range of fibrillar, oligomeric and monomeric protein preparations for use in neurodegenerative disease research including alpha synuclein, beta synuclein, gamma synuclein, tau, amyloid beta, SOD1 and TTR. Our goal is to be the world leader in the development and supply of active, pathology-inducing protein aggregates to assist scientists with disease model development and accelerate neurodegenerative disease drug discovery.

Tau Pre-formed Fibrils (PFFs), Oligomers, Filaments & Monomers 

Tau Pre-formed Fibrils (PFFs)

StressMarq manufactures active tau protein constructs to help researchers study tau aggregation, a hallmark of neurodegenerative diseases including Alzheimer’s. StressMarq was the first commercial source of active tau pre-formed fibrils (PFFs) for neuroscience research, and offers the broadest range of tau constructs to researchers worldwide.

The process of tau aggregation can be seeded by active tau PFFs, which recruit monomers to form larger tau fibrils. This is demonstrated in thioflavin T assays, where an increase in fluorescence – indicative of tau fibrillization – is seen when active tau PFFs are combined with active tau monomers.

StressMarq offers a wide selection of tau monomers, pre-formed fibrils (PFFs) and oligomers with various isoforms, lengths, and mutations.

Product List | PFFs

Tau & Alpha Synuclein Co-Polymer Fibrils (Mixed Fibrils/PFFs) 

StressMarq’s co-polymer fibrils are developed by co-incubating monomers together to form fibrils that contain both tau and alpha synuclein proteins within a single fibril. These co-polymer fibrils have been demonstrated to seed fibril formation of both tau monomers and of a mixture of alpha synuclein and tau monomers.

Product List | Co-Polymer Fibrils

Tau Oligomers 

Tauopathies such as Alzheimer’s Disease (AD) are characterized by neurofibrillary tangles containing hyper-phosphorylated tau fibrils, with consensus that tau oligomers are the most toxic species initiating neurodegeneration. StressMarq’s tau oligomers exert a dose-dependent toxicity to hippocampal neurons.

Product List | Oligomers

Tau Monomers

StressMarq’s tau monomers are capable of aggregation. They do not show neurodegenerative activity.

Product List | Monomers

Selected Scientific & Product Information

Tau Isoforms

Tau-441 (2N4R) is the longest isoform found in the adult human brain, with a molecular weight of approximately 46 kDa. Additional tau isoforms present in the adult human brain include Tau-381 (1N3R), Tau-383 (0N4R) and Tau-412 (1N4R). Tau-352 is expressed in the fetal brain.¹ NMR data indicates that both 3R and 4R tau are incorporated into AD-tau seeded fibrils.² All tau isoforms play a crucial role in microtubule stabilization and dynamics in neurons, however, their dysregulation has been associated with neurodegenerative diseases including Alzheimer’s disease and frontotemporal dementia.

Tau Fragments

Tau fragments, including K18 and dGAE, also have significance in Alzheimer’s disease research.

K18 tau is a truncated form of human tau containing only the 4 microtubule binding repeats (4R), with a molecular weight of approximately 15 kDa. StressMarq’s K18 tau PFFs have been shown to induce aggregation and pathology in transgenic mice.

The dGAE fragment (amino acids 297-391), with a molecular weight of approximately 10 kDa, has been found in the core of Paired Helical Filaments (PHFs) from AD brains and assembles into PHF-like fibrils in vitro without additives or templates.³ Recent studies have led to the development of optimized dGAE fibrils, purified and fibrilized under specific conditions, which closely mimic PHFs isolated from Alzheimer’s disease brains.⁴

Tau Mutations

Tau proteins are available in both wild-type and mutated forms. P301S and P301L mutations occur in exon 10 and are associated with frontotemporal dementia. The P301S mutation reduces tau’s ability to assemble microtubules, while the P301L mutation promotes beta-sheet formation and the formation of PHFs. Transgenic mouse models carrying both P301S and P301L mutations are used extensively in tau research. The K280 deletion mutation is also associated with frontotemporal dementia and promotes fibrillization into PHFs in the absence of heparin and other inducers.⁵ Additionally, the C322A mutation also increases tau’s ability to form PHFs.³

While the majority of StressMarq tau proteins are expressed in E. coli, preparations expressed in Baculovirus/Sf9 and Chinese Hamster Ovary (CHO) cells are also available. Using these expression systems results in recombinant proteins with post-translational modifications such as phosphorylation or glycosylation and may better mimic tau that is found in human AD brains.

Unlike most amyloidogenic proteins such as alpha synuclein, tau monomers exhibit a low propensity to spontaneously aggregate into fibrils. However, various scaffolds including heparin, RNA and fatty acids (i.e. arachidonic acid) can stimulate tau aggregation by providing surfaces or templates for the nucleation and fibril growth. Most tau preparations require heparin for fibrillization, however, excess heparin is removed post-fibrillization. Studies have shown that certain types of RNA molecules, including tRNA, rRNA, and mRNA can interact with tau and promote its aggregation into fibrils.⁶ StressMarq’s soluble tau filaments are fibrillized using t-RNA as a scaffold. According to literature, certain mutations and post-translational modifications have been shown to enhance tau’s aggregation propensity, leading to fibrillization without the need for scaffolds.⁷ StressMarq offers a range of tau preparations including dGAE tau, K18 K280 deletion mutant tau, and post-translationally modified tau expressed in baculovirus/Sf9 and mammalian cells, which are generated without any induction scaffolds.

References

1. 1. Goedert, et al. (1989) Neuron 3(4):519-26.
   2. Dregni, A.J. et al. (2022) Nat Commun 13, 2967. 
   3. Al-Hilaly, Y.K. et al. (2017) J. Mol. Biol. 429(23):3650-3665.
   4. Lovestam, S. et al. (2022) eLife. 11: e76494.
   5. Von Bergen, M. et al. (2001) J Biol Chem. 276(51):48165-48174.
   6. Zwierzchowski-Zarate A.N. (2022) J. Biol. Chem. 298(8):102132. 
   7. Oakley, S. et al. (2020) Front. Neurol. 11. 

Selected Tau Product Images

Immunohistochemistry analysis of P301L mouse hippocampus injected with Recombinant Tau (K18) P301L Mutant Protein Pre-formed Fibrils, catalog# SPR-330 shows seeding of tau pathology at injection site nine weeks post-injection. AT8 (pSer202/pThr205) tau antibody shows tangle-like inclusions. Inset: negative control. Experiments performed at reMYND.

TEM of Recombinant Tau dGAE (297-391) AD-mimic Pre-formed Fibrils, catalog# SPR-502.

Product Citations

StressMarq’s proteins for neurodegenerative disease research have been cited in many peer-reviewed scientific journals. Below is a list of the most recent product citations for our tau proteins. A complete list of citations for tau proteins can be seen here.

Most Recent Tau Citations

• FGFR3 drives Aβ-induced tau uptake. Kim, D. et al. Exp Mol Med. 2024.
  • Catalog# SPR-330: Human Recombinant Tau (K18) P301L Mutant Pre-formed Fibrils

• Reversal of neuronal tau pathology, metabolic dysfunction, and electrophysiological defects via adiponectin pathway-dependent AMPK activation. McGregor, E.R. et al. bioRxiv. 2024.
  • Catalog# SPR-329: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils

• ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes. Eisenbaum, M. et al. Glia. 2024.
  • Catalog# SPR-329-A488: Human Recombinant Tau-441 (2N4R) P301S Mutant Pre-formed Fibrils: ATTO 488
  • Catalog# SPR-479 & Catalog# SPR-480: Human Recombinant Tau-441 (2N4R) Wild-Type Monomers & Pre-formed Fibrils

Supplemental Learning Materials

Technical Support Resources

• Handling Instructions | Tau
• Protocols | Tau
• Sonication Protocol | PFFs
• Frequently Asked Questions | Neuro Proteins

Selected Media from the StressMarq YouTube Channel 

• Video | Tau Pre-formed Fibrils for Neurodegenerative Disease Modelling
• Webinar | Tools for Alzheimer’s & Parkinson’s Research | Presented by Dr. Jacob McPhail, R&D Scientist, StressMarq
• Open Theatre | Fibrillar & Oligomeric Constructs of Neurodegenerative Disease Asssociated Peptides | Presented by Dr. Ariel Louwrier, President & CEO, StressMarq

Selected Articles from the StressMarq Blog

• Tau Fibrillar Constructs | Learn about tau fibrils, filaments, isoforms, and mutations of interest.
• Reversing Tau Pathology Through Mitochondrial Regulation | Mitigation of mitochondrial defects induced by tau pathology, using an adiponectin receptor agonist.
• A Neuron/Astrocyte Model of Tau Pathology | A low-cost, miniaturized 3-D neuron/astrocyte co-culture model for studying tauopathy.
• Microglial Activation in Alzheimer’s Disease | CDK1 regulates microtuble cytoskeletal changes underlying microglial activation in Alzheimer’s disease.

Have a question about Tau?